CDK4 and breast cancer: Other reports also suggest that premalignant senescent cells induced by CDK4/6 inhibition do not acquire pro‐tumorigenic and detrimental properties in patients with breast cancer patients, suggesting that these effects could be beneficial for senescence surveillance [100].